Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROSI gene rearrangement after treatment with crizotinib

被引：32

作者：

Bos, M. ^{[1
]}

Gardizi, M. ^{[1
]}

Schildhaus, H. U. ^{[2
]}

Heukamp, L. C. ^{[2
]}

Geist, T. ^{[3
]}

Kaminsky, B. ^{[4
,5
]}

Zander, T. ^{[1
]}

Nogova, L. ^{[1
]}

Scheffler, M. ^{[1
]}

Dietlein, M. ^{[6
]}

Kobe, C. ^{[6
]}

Holstein, A. ^{[6
]}

Maintz, D. ^{[7
]}

Buettner, R. ^{[2
]}

Wolf, J. ^{[1
]}

机构：

[1] Univ Hosp Cologne, Dept Internal Med 1, Ctr Integrated Oncol Koln Bonn, Cologne, Germany

[2] Univ Hosp Cologne, Inst Pathol, Ctr Integrated Oncol Koln Bonn, Cologne, Germany

[3] Florence Nightingale Hosp, Dept Internal Med Pneumol & Sleep Med, Dusseldorf, Germany

[4] Bethanien Hosp, Clin Pneumol, Solingen, Germany

[5] Bethanien Hosp, Clin Allergol, Solingen, Germany

[6] Univ Hosp Cologne, Dept Nucl Med, Ctr Integrated Oncol Koln Bonn, Cologne, Germany

[7] Univ Hosp Cologne, Inst & Policlin Radiol Diagnost, Ctr Integrated Oncol Koln Bonn, Cologne, Germany

来源：

LUNG CANCER | 2013年 / 81卷 / 01期

关键词：

NSCLC; ROS1; Personalized medicine; Lung cancer; Crizotinib;

D O I：

10.1016/j.lungcan.2013.02.018

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A 55-year-old Caucasian woman with lung adenocarcinoma stage IV presented with repeated relapse after treatment with cytotoxic chemotherapy (carboplatin, gemcitabine, docetaxel, pemetrexed) and targeted agents (erlotinib, cetuximab, sunitinib). Comprehensive molecular diagnostics (EGFR-, ALK-, RAS-, BRAF-, PIK3CA-, HER2- and DDR2-aberrations) were performed and failed initially to detect any driver mutation. While the patient suffered from rapid deterioration of her general condition, in particular from progressive dyspnea due to lung metastases, we implemented screening for RET- and ROS1 translocations into our molecular diagnostic program based on recent reports of these new molecular subgroups in lung adenocarcinoma. On retesting the patient's tumor sample was found to harbor a ROS1-translocation. The patient was subsequently treated with crizotinib and experienced a pronounced clinical improvement corresponding to a complete metabolic response in 18F-FDG-PET and a good and confirmed partial response in CT (RECIST 1.1). Our case exemplifies the need for rapid implementation of newly discovered rare genetic lung cancer subtypes in routine molecular diagnostics. (C) 2013 Elsevier Ireland Ltd. All rights reserved.

引用

页码：142 / 143

页数：2

共 3 条

[1] The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer [J].

Acquaviva, Jaime ;

Wong, Ricky ;

Charest, Al .

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2009, 1795 (01) :37-52

[2] ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers [J].

Bergethon, Kristin ;

Shaw, Alice T. ;

Ou, Sai-Hong Ignatius ;

Katayama, Ryohei ;

Lovly, Christine M. ;

McDonald, Nerina T. ;

Massion, Pierre P. ;

Siwak-Tapp, Christina ;

Gonzalez, Adriana ;

Fang, Rong ;

Mark, Eugene J. ;

Batten, Julie M. ;

Chen, Haiquan ;

Wilner, Keith D. ;

Kwak, Eunice L. ;

Clark, Jeffrey W. ;

Carbone, David P. ;

Ji, Hongbin ;

Engelman, Jeffrey A. ;

Mino-Kenudson, Mari ;

Pao, William ;

Iafrate, A. John .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (08) :863-870

[3]

Ou SI, 2012, ANN ONCOL S9, V23, pix389

← 1 →